Arcturus Therapeutics (ARCT)

• Market cap: $511M
• 1 day: 4.27%
• 5 days: 6.63%
• 1 month: 5.08%
• 3 months: 52.39%
• 6 months: 37.07%
• Year to date: 10.25%
• 1 year: -8.42%
• 5 years: -59.86%
• 10 years: -67.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.

Employees: 176

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

157% more call options, than puts

Call options by funds: $5.16M | Put options by funds: $2.01M

23% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 40

19% more capital invested

Capital invested by funds: $283M [Q1] → $336M (+$53.4M) [Q2]

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

1% less funds holding

Funds holding: 144 [Q1] → 143 (-1) [Q2]

3.13% less ownership

Funds ownership: 98.14% [Q1] → 95.01% (-3.13%) [Q2]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35
• Avg. target: $48
• High target: $60

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew S. Fein	$60	Buy Assumed	4 Sep 2025
Leerink Partners Lili Nsongo	$54	Outperform Maintained	22 Aug 2025
Wells Fargo Yanan Zhu	$42	Overweight Maintained	12 Aug 2025
Citigroup Yigal Nochomovitz	$49	Buy Maintained	12 Aug 2025
Scotiabank Greg Harrison	$35	Sector Outperform Maintained	2 Jul 2025